scholarly journals S2585 Incidental Finding of Intrahepatic Cholangiocarcinoma Presenting Radiographically as Hepatocellular Carcinoma in a Liver Transplant Candidate

2021 ◽  
Vol 116 (1) ◽  
pp. S1088-S1089
Author(s):  
Fayssa Salomon ◽  
Ali Wakil ◽  
Mujtaba Mohamed ◽  
Gopala Koneru ◽  
Nikolaos Pyrsopoulos
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplant ◽  
Intrahepatic Cholangiocarcinoma ◽  
Incidental Finding ◽  
Liver Transplant Candidate ◽  
Transplant Candidate

Determination of hepatocellular carcinoma grade by needle biopsy is unreliable for liver transplant candidate selection

2017 ◽  
Vol 23 (9) ◽  
pp. 1123-1132 ◽  
Author(s):  
Colin M. Court ◽  
Michael P. Harlander-Locke ◽  
Daniela Markovic ◽  
Samuel W. French ◽  
Bita V. Naini ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplant ◽  
Needle Biopsy ◽  
Candidate Selection ◽  
Liver Transplant Candidate ◽  
Transplant Candidate

Frailty and the Potential Liver Transplant Candidate

2021 ◽  
pp. 27-32
Author(s):  
Matthew J. Armstrong ◽  
Jennifer C. Lai
Keyword(s):  
Liver Transplant ◽  
Liver Transplant Candidate ◽  
Transplant Candidate

Antibody Development to HCV Alternate Reading Frame Protein in Liver Transplant Candidate and its Computational Analysis

2020 ◽  
Vol 17 (2) ◽  
pp. 154-170 ◽  
Author(s):  
Zahra Musavi ◽  
Tayebeh Hashempour ◽  
Javad Moayedi ◽  
Behzad Dehghani ◽  
Farzaneh Ghassabi ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Transplant ◽  
Chronic Patients ◽  
Advanced Liver Disease ◽  
Reading Frame ◽  
Alternate Reading Frame Protein ◽  
Physicochemical Features ◽  
Liver Transplant Candidate ◽  
Transplant Candidate ◽  
Chronic Hcv

Background:: HCV Alternate Reading Frame Protein (ARFP) is a frameshift product of HCV-core encoding. Here, we characterized specific anti-ARFP antibodies in Liver Transplant Candidate (LTC) and chronic HCV-infected patients. Methods:: The ARFP gene was cloned and the recombinant protein was purified using Nickel chromatography and confirmed by western blotting. ELISA was developed using recombinant core-1a, core- 1b, ARFP-1a protein, and 99-residue synthetic ARFP 1b peptide. By several Bioinformatics tools, general properties, immunogenic epitopes, and structures of these proteins were obtained. Results:: The seroprevalence of anti-core and anti-ARFP antibodies was 100% in LTC patients, but only 75.2% and 94.3% of chronic patients had evidence of anti-ARFP and anti-core antibodies, respectively. In-silico results demonstrated physicochemical features, antigen properties and potential interactors that could describe progression toward advanced liver disease. Conclusion:: As the first report, the prevalence of anti-ARFP antibodies in LTC patients is of the order of 100% and titer of anti-ARFP antibody was significantly higher in LTC patients compared to chronic individuals, suggesting the possible role of ARFP in the progression toward advanced liver disease. In addition, docking analysis determined several interactor proteins such as prefoldin 2, cathepsin B, vitronectin, and angiotensinogen that have an important role in progression to chronic infection and liver disease development.

scholarly journals Thrombosis and coagulopathy in the liver transplant candidate and recipient

2017 ◽  
Vol 9 (1) ◽  
pp. 11-17 ◽  
Author(s):  
R. Todd Stravitz
Keyword(s):  
Liver Transplant ◽  
Liver Transplant Candidate ◽  
Transplant Candidate

Management of alcohol-related liver disease in liver transplant candidate patients

2020 ◽  
Vol 66 (3) ◽  
Author(s):  
Gianni Testino ◽  
Patrizia Balbinot ◽  
Silvia Leone ◽  
Rinaldo Pellicano
Keyword(s):  
Liver Disease ◽  
Liver Transplant ◽  
Liver Transplant Candidate ◽  
Transplant Candidate ◽  
Related Liver Disease

Care of the Liver Transplant Candidate

2011 ◽  
Vol 15 (4) ◽  
pp. 779-806 ◽  
Author(s):  
Hui-Hui Tan ◽  
Paul Martin
Keyword(s):  
Liver Transplant ◽  
Liver Transplant Candidate ◽  
Transplant Candidate
Sign in / Sign up

Export Citation Format

Share Document